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Through the collaboration of many institutions across the globe, the Distributed
Drug Discovery project founded at Indiana University-Purdue University Indianapolis
seeks to aid in the development of drugs for the developing world. In response to two
antimalarial assay hits, our team at Abilene Christian University has synthesized many
unnatural amino acid analogs using resin-based combinatorial chemistry. Proton nuclear
magnetic resonance spectroscopy has been used to characterize the compounds and thin
layer chromatography to determine purity. All compounds were purified on hypersep
cyanosilica columns.
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Introduction
“Distributed Drug Discovery” (D3) is a concept developed by a team led by
William L. Scott at Indiana University-Purdue University Indianapolis (IUPUI) to
address some of the larger problems encountered in drug discovery in relation to
underdeveloped nations.1 One of these problems is the pharmaceutical industry develops
drugs for economic gain, thus diseases plaguing the developing world are often ignored.1
One of the goals of D3 is collaboration between non-profit organizations and institutions
that can focus on these neglected diseases.
Antimalarial compounds from Screening
qHTS-1
qHTS-2

Potency (⎧M): 10.4179

2.9632

Figure 1. Two amino acid analogs that demonstrated biological activity in a validated assay testing for
inhibition of apicoplast formation in Plasmodium falciparum.3

In this collaboration, the large workload of the drug discovery process can be
distributed to many smaller groups working with one another as well as aiding in the
educational process through real-world application of drug synthesis in a global project.1
Combinatorial chemistry2 is employed to aid in the drug discovery process along with
inexpensive equipment and procedures, that were developed specifically for this effort.3
There are three main stages in the D3 project: molecule library planning/computational
analysis, chemical synthesis, and biochemical screening.1 The first stage involves
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creating virtual catalogues of potential drug molecules based on known compounds,
which possess the desired biological activity (Fig. 1). The second stage involves
synthesizing the potential drug molecules. The third stage is the biological screening of
the synthesized molecules for activity. Our research focuses on the second stage through
the use of resin-based chemistry with the Bill-board apparatus developed at IUPUI to
simplify the small-scale parallel synthesis of multiple compounds. The general reaction
scheme for this synthesis can be seen in Scheme 1 and an example Bill-board reaction in
Figure 2. The details of the actual synthesis are covered in the experimental section.

Scheme 1. Benzophenone imine Gly-Wang resin alkylation-acylation reaction scheme used to create
unnatural amino acid analogs.3
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Figure 2. Sample 2x3 reaction array for combinatorial chemistry on Bill-board apparatus. The symbols A1
through B3 represent the chemical compound synthesized in that reaction vessel.

Discussion
In order to use resin-based chemistry, the Fmoc protecting group on the resinbound glycine must be replaced with a benzophenone imine group for our reactions
(Scheme 2). This benzophenone imine group helps to facilitate the alkylation of the alpha
carbon on the resin molecule. The procedure for producing this resin is detailed in the
experimental section. The resin is synthesized in the lab, as the preparation is less
expensive than buying the resin already prepared. The resin prepared for this work had
comparable results to the resin previously prepared by another student in a small 4 x 4
test plate. This prepared resin was used for all of the syntheses in this report.

Scheme 2. Preparation of Fmoc Gly-Wang resin for benzophenone imine Gly-Wang resin.5
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With the prepared resin, our team pursued the synthesis of compound analogs of
the two molecules that were active in the antimalarial screen. The alkylating (R1) and
acylating (R2) reagents were chosen to allow for the synthesis of compounds that vary in
molecular properties in order to explore the structure-activity relationships for this class
of compounds. This work was focused on bicyclic compounds as both alkylating and
acylating reagents. There was little success in using certain bicyclic alkylating reagents
(ACU-ACD-29 A2, A3, B2, B3), especially 2-(bromomethyl) naphthalene. The TLC on
A2 and B2 had many additional spots and the NMR was also complex, revealing that the
reaction did not proceed selectively. The same effect was noted on the A3 and B3
compounds but there were not as many byproducts, the alkylation with 1-(bromomethyl)
naphthalene seeming to be more successful.
With the mixed results of the bicyclic alkylating reagent plate, bicyclic acylating
reagents were tested next. The first plate (ACU-ACD-45 A1-B3) indicated very little side
product on TLC. The NMR spectra also indicated relatively pure product. As far as could
be observed from the characterization done, these compounds were very successful in
synthesis. The same was noted for ACU-ACD-69 with a few slight possible impurities.
The high yields, with most being above quantitative, likely indicate that either solvent
was still present when the weights were obtained or there were impurities present.
Bicyclic compounds used for alkylation were revisited with plate ACU-ACD-85.
In this trial, the amount of 2-(bromomethyl) naphthalene was increased to 3 equivalents
to see if increasing the concentration would facilitate the reaction for better results in A2
and B2. In A3 and B3, the alkylation was catalyzed by the addition of KI to react in situ
with the 2-(bromomethyl) naphthalene to replace the bromine with iodine to act as a
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better leaving group. The results of this plate were mixed, as there seemed to be two
products seen on thin layer chromatography (TLC) overlapping each other. The NMR
spectra look relatively clean with a few possible impurities. Another indication of the
presence of impurities were the greater than quantitative yields for this plate.
Compound purifications were carried out using cyanosilica stationary phase
chromatography cartridges. Results are reported in the table below and the general
procedure can be found in the results section. Overall, the procedure used was relatively
successful with 10 compounds successfully purified. All compounds except for ACD-29
compounds and ACD-45-A compounds were successfully purified. ACD-29 compounds
were not purified due to previous complications with a different silica column.7
Purifications were then halted until new cartridges could be obtained. These hypersep
cyanosilica columns were then tested with a previously made compound and noted to be
successful in the purification process.8 There were some issues with the ACD-85-B
compounds as well as ACD-45-B1. ACD-45-B1 seemed to have changed properties after
being stored for a long period of time. This compound would not dissolve in the 5%
methanol/dichloromethane solution in which the other compounds dissolved to be loaded
on the column. The compound initially appeared to dissolve until a yellow, greasy
looking substance began to form. Even the addition of extra methanol did not dissolve
this substance and the purification was abandoned. The ACD-85-B compounds were
successfully transferred onto the silica columns, however, there was not a significant
return of product. Even after washing the column with a polar solvent, there was no
further product was removed from the column. Due to these results, it is suggested that
the compound likely decomposed on the column. The procedure that is included in the
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experimental section became the standard procedure for all purifications due to the large
success in returning product for most purifications. The results of the purifications are
reported below in Table 1.
Some of the alkylating and acylating reagents employed in these syntheses were
synthesized in lab either due to the cost of the reagent or the reagent being unavailable
commercially. The first reagent synthesis was 4-(methoxyphenyl)methyl
methanesulfonate as previously attempted by another student.6 Unfortunately the same
issue occurred as previously encountered as the 4-(methoxyphenyl) methanol reacted
with itself to form an ether. The synthesis was abandoned as it is unknown how to solve
the issue and to obtain the methanesulfonate.
Another student previously tried to synthesize the bromine derivative of 4(chloromethyl) anisole, but it was unstable.9 The chlorine derivative was attempted, but
due to adding triethylamine in error, the thionyl chloride did not react with the 4methoxybenzyl alcohol. The recovered alcohol with a slight amount of triethylamine was
used to attempt the synthesis again without additional triethylamine, but the reaction was
unsuccessful, as the alcohol still did not react.
The final synthesis attempted was 3-pyridyl methanol from nicotinic acid. The
first procedure used sulfuric acid in methanol to synthesize methyl nicotinate before
using sodium borohydride to reduce to the alcohol.10 The esterification in the first step of
this procedure was successful with the greatest yield at about 47%. However, with the
reduction, results from the literature procedure could not be reproduced. The second
procedure used BF3•Et2O with sodium borohydride to reduce the nicotinic acid to 3pyridyl methanol.11 Most of the product obtained was decomposed THF and the desired
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product was not noted through characterization with 1H NMR. Another product was
noted with the decomposed THF, but could not be readily identified. This product was
separated from the decomposed THF through column chromatography with silica gel.
This by-product seemed to have changing properties as it would first be a very thick oil
that would solidify after a while. Other characteristics were noted to change during the
synthesis such as change in color of the aqueous layer from yellow to colorless/pale
yellow. Even after isolating this other product, it could not be readily characterized. It is
possible that the product is an unstable borate compound.
Table 1. Alkylating and acylating reagents used for each amino acid analog synthesis. See Scheme 1 for
core amino acid structure.13 *Compound serial numbers are reported in the format of “institution-student
initials-page number-Bill-board position.”

Serial Number*

crude
% yield
37.6

% Return

ACU-ACD-29A2

46.6

0%

ACU-ACD-29A3

98.8

not
purified15

ACU-ACD-29B1

84.7

not
purified15

ACU-ACD-29B2

70.9

0%

ACU-ACD-29B3

>100

not
purified15

ACU-ACD-29A1

Alkylating Reagent, R1

Acylating Reagent, R2

not
purified15
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Serial Number*

Alkylating Reagents, R1

Acylating Reagents, R2

crude
% yield

% return

ACU-ACD-45A1

>100

not
purified16

ACU-ACD-45A2

>100

not
purified16

ACU-ACD-45A3

88.7

not
purified16

ACU-ACD-45B1

>100

not
purified17

ACU-ACD-45B2

>100

19.4

ACU-ACD-45B3

>100

13.3

ACU-ACD-69A1

98.8

34.7

ACU-ACD-69A2

96.9

34.5

ACU-ACD-69A3

>100

31.3

ACU-ACD-69B1

>100

15.7

ACU-ACD-69B2

>100

26.8

ACU-ACD-69B3

>100

16.2

ACU-ACD-85A1

>100

29.7

14
Serial Number*

Alkylating Reagents, R1

Acylating Reagents, R2

crude
% yield

% return

ACU-ACD-85A2

>100

30.218

ACU-ACD-85A3

>100

ACU-ACD-85B1

>100

0

ACU-ACD-85B2

>100

018

ACU-ACD-85B3

>100

Conclusion
The bicyclic ring systems work as better acylating reagents than alkylating
reagents. If used as alkylating reagents, the use of a catalyst such as KI or increasing the
concentration helped to facilitate the alkylation, though more methodology development
is needed. Altogether, there were 24 amino acid analogs synthesized. ACD-29 A2, A3,
B2, and B3 had many impurities and the syntheses were not successful. Other plates were
purified to varying degrees of success. Overall, the 10 compounds successfully purified
and 3 additional compounds are ready to be sent for biological assay. Since this project is
relatively new, it is unsure what the results of the biological assay will report. However,
better selectivity for creating more potent molecules for possible antimalarial analogs can
be determined from the results of the biological assay.
While there are no conclusions to exactly what is occurring in the 3-pyridyl
methanol synthesis, identification of what is happening can be used to make necessary

15
changes to the procedure to get more desirable results. The main issue may lie with the
borate not hydrolyzing properly and more success may be found with quenching the
reaction at a warmer temperature instead of in the ice bath. Altogether 4 reagent
syntheses were attempted and were unsuccessful.
Experimental
Preparation of Benzophenone imine Gly-Wang resin5
5.08g (3.56 mmol) Fmoc Gly-Wang resin (from Creosalus, loading factor 0.7
mmol/g) was added to a 100 mL fritted peptide reaction vessel and washed with 42 mL of
30% piperidine in 1-methyl-2-pyrrolidinone (NMP). Another 42 mL of the 30% solution
was added and contents shaken for 30 minutes at room temperature. Waste was drained
from the vessel and resin washed with 5 x 40 mL NMP. Benzophenone imine (5.97 mL,
35.6 mmol) in 42 mL NMP was added to the vessel along with 1.77 mL acetic acid. The
contents were shaken for 18 hours at room temperature. The solution was drained and the
resin washed with 5 x 40 mL NMP, 5 x 40 mL CH2Cl2, and then dried under a vacuum. A
total of 4.74 g (93% yield) was collected and placed in a vacuum desiccator for storage.
Resin-based Unnatural Amino Acid Synthesis
Alkylation - Approximately 71.0 mg of Benzophenone Imine Gly-Wang Resin
(loading factor 0.7 mmol/g) was weighed out for each reaction vessel (six total) and
placed in each vessel. The Bill-board was placed on the drain tray and each vessel was
washed with 3 x 3 mL of 1-methyl-2-pyrrolidinone (NMP). The screw caps with clean
septa were placed on the bottom of each vessel. Alkylating reagent 1 [0.5 mL of 0.2 M
solution in NMP, 100 µmol, 2 equivalent] was added to A1 and B1. Alkylating reagent 2
[0.5 mL of 0.2 M solution in NMP, 100 µmol, 2 equivalent] was added to A2 and B2.
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Alkylating reagent 3 [0.5 mL of 0.2 M solution in NMP, 100 µmol, 2 equivalent] was
added to A3 and B3. The base, tert-butylimino-tri(pyrrolidino)phosphorane (BTPP) [0.5
mL of 0.2 M solution in NMP, 100 µmol, 2 equivalent], was added to all six reaction
vessels. The tops were sealed with screw tops and septa. The Bill-board was then placed
on the orbital shaker for 48 to 72 hours at room temperature.
Hydrolysis - The Bill-board was removed from the orbital shaker, inverted and
the bottom caps removed from the vessels. The board was then reverted and placed on the
drain tray and top caps removed to allow alkylating reagents and solutions to drain. The
resin was then washed with 1 x 3 mL tetrahydrofuran (THF). The bottoms of the vessels
were recapped with clean caps. To each vessel, 2.5 mL of a 1N solution of HCl/THF
(1:2) was added. The tops were capped and the Bill-board was placed back on the shaker
for 20-30 minutes at room temperature. The Bill-board was removed, caps removed as
done previously. On the drain tray, waste was removed before the resin was washed with
1 x 3 mL THF each vessel.
Acylation - Two different acylating methods were used depending on whether the
acylation reagent was an acid chloride or a carboxylic acid.
For an acid chloride, the resin bound compound was washed with 1 x 3 mL NMP
each vessel and the bottoms of the vessels recapped. Acylating reagent A [0.5 mL of 0.3
M solution in NMP, 150 µmol, 3 eq] was added to the three vessels in row A (A1-3).
Acylating reagent B [0.5 mL of 0.3 M solution in NMP, 150 µmol, 3 eq] was added to
the three vessels in row B (B1-3). Then DIEA (N,N-diisopropylethylamine) [0.5 mL of
0.3 M solution in NMP, 150 µmol, 3 eq] was added to all six vessels. The tops of the
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vessels were capped and the Bill-board was placed on the orbital shaker for 48-72 hours
at room temperature.
For a carboxylic acid, the resin was washed with 3 x 2.5 mL of a 0.2 M solution
of DIEA in NMP and 2 x 2.5 mL NMP. The bottoms were recapped. Acylating reagent A
[1.0 mL of 0.25 M A and 0.25 M HOBt (hydroxybenzotriazole) in NMP, 250 µmol, 5 eq
for both A and HOBt] was added to the three vessels in row A (A1-3). Acylating reagent
B [1.0 mL of 0.25 M in 0.25 M HOBt (hydroxybenzotriazole) in NMP, 250 µmol, 5 eq
for both B and HOBt] was added to the three vessels in row B (B1-3). The coupling
reagent N,N-diisopropylcarbodiimide (DIC) [0.5 mL of 0.5 M in NMP, 250 µmol, 5 eq]
was added to all six reaction vessels. The tops of the vessels were recapped and the Billboard was placed on the orbital shaker for 48-72 hours at room temperature.
Cleavage of Products from Resin - Each reaction vessel was washed with 2 x 3
mL NMP, 2 x 3 ml THF, and 3 x 3 mL dichloromethane (DCM). The bottoms of the
vessel were recapped and 2 mL of a trifluoroacetic acid (TFA), water solution (95:5
TFA/H2O) was added to each vessel. The vessels were capped and the Bill-board was
placed on the orbital shaker for 30 minutes. The filtrate was collected in tared vials by
inverting the Bill-board, removing the bottom caps, putting a vial over each vessel,
placing the collection rack over the vials, and reverting the Bill-board. The resin was
washed with 2 mL TFA solution and 2 mL DCM for each vessel. The vials in the
collection rack were placed in an apparatus that allows for the evaporation of solvents
under a stream of nitrogen. This system was connected to a bubbler to capture evaporated
TFA in a solution of 2 M NaOH. Once the samples were dried down, they were
transferred to be heated slightly under vacuum to ensure all solvents were removed. After
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this, the samples were characterized with 1H NMR to analyze the compounds’ structure
to ensure that the alkylation and acylation were successful.
Purification of Unnatural Amino Acids
The standard procedure for purifications was as follows. The desired product was
dissolved in 0.3 mL 5% methanol/dichloromethane and loaded onto the silica column and
allowed to dry. Then the first fraction was collected with 2 mL of hexanes. Fractions 2-3
were collected with 1 mL 75/25 hexanes/acetone. Varying amounts of fractions were
collected with the same 75/25 solution as previously. The number of fractions required
was different for each compound.11 If necessary, the polarity of the solution was
increased as needed for additional fractions by increasing the percentage of acetone in the
solvent. Each purification was monitored by TLC to note when different products were
coming out of the column and when the purification was complete and no other product
was being removed from the column. Once the purification was complete, the solvent
was allowed to evaporate. Once evaporated, a full TLC was done to compare different
fractions to a sample of the original products before purification to determine which
fractions contained the desired product. Once the potential desired product was found, the
appropriate fractions were combined in NMR solvent (CDCl3 and CD3OD) and a
H1NMR was run to confirm that the desired product was recovered. After it was
confirmed that the desired product was obtained, the product dissolved in the solvent was
transferred to a tared vial and the solvent allowed to evaporate. Once all solvent
evaporated, the vial could be massed to determine the return of product.
1

H NMR Data for Unnatural Amino Acids
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All compounds synthesized were characterized with 1H NMR with a Varian
EM360A NMR spectrometer at 60 MHz in CDCl3 and CD3OD. The spectra tended to
have similar characteristics with the methyne and methylene protons usually indicative of
our compounds. There is some variability depending on the substituent. The methyne
proton usually appeared as a triplet or sometimes a doublet of doublets with a chemical
shift of approximately 4.7 to 5.2 PPM from TMS. The methylene protons usually
appeared as a doublet of doublets with a chemical shift of approximately 3.2-3.7 PPM
from TMS. The below compounds are representative of the other compounds
synthesized.
ACU-ACD-29 A3: ™ 8.16-7.23 (m, 12 H), 4.92 (t, 1 H), 3.41 (m, 2 H). 11
ACU-ACD-29 B3: ™ 8.87 (m, 2 H), 8.43-7.42 (m, 9 H), 5.11 (t, 1 H), 3.76 (m, 2 H).
ACU-ACD-45 A2: ™ 8.23 (s, 1H), 7.82-7.30 (m, 10 H), 5.04 (t, 1 H), 3.22 (d, 2 H), 2.30
(s, 3 H).
ACU-ACD- 45 B2: ™ 9.65 (s, 1 H), 9.26 (s, 1 H), 8.56-8.17 (m, 8 H), 5.33 (d, 1 H), 3.54
(d, 2 H), 2.56 (s, 3 H).
ACD-ACD-69 A1: ™ 8.56 (s, 1 H), 8.42-7.36 (m, 10 H), 5.38 (t, 1 H), 3.67 (d, 2 H),
2.73(s, 3 H).
ACU-ACD-69 B1: ™ 9.32 (s, 1 H), 8.93 (s, 1 H), 8.44-7.81 (m, 8 H), 5.02 (d, 1 H), 3.23
(d, 2H), 2.32 (s, 3 H).
ACU-ACD-85 A3: ™ 7.90-7.36 (m, 12 H), 5.15 (t, 1 H), 3.41 (m, 2 H). 7
ACU-ACD-85 B3: ™ 9.05 (s, 1 H), 8.76 (m, 1 H), 8.40 (1 H), 8.29 (s, 1 H), 7.88-7.35
(m, 7 H), 5.15 (d, 1 H), 3.44 (m, 2 H).
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